Pomerantz Law Firm Launches Investigation into Cellectis S.A. Investor Claims
Pomerantz Law Firm Investigates Cellectis S.A. Investor Claims
In recent developments, Pomerantz LLP, a prominent law firm known for its expertise in securities class action litigation, has announced an investigation on behalf of investors in Cellectis S.A. (NASDAQ: CLLS). The focus of this investigation is to examine whether Cellectis, along with certain officers and directors, may have engaged in securities fraud or other unlawful business practices that could have impacted investor decisions.
Significant Announcements and Their Consequences
On September 14, 2026, Cellectis revealed a strategic shift in its therapeutic focus. The company stated its intention to prioritize in vivo gene editing therapies, specifically HEAL-101 and HEAL-201, while discontinuing the development of CAR-T cell therapies, which included lasme-cel and eti-cel. This drastic pivot raised concerns among investors regarding the company's financial health and future direction.
Cellectis's Chief Medical Officer, Adrian Kilcoyne, highlighted the challenges the company faces in financing these therapies, stating that they could not support the ongoing development of eti-cel and lasme-cel due to
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.